Novavax (NVAX) Long-Term Investments (2012 - 2013)

Novavax's (NVAX) quarterly Long-Term Investments came in at $1.1 million in Q1 2013, down 82.08% quarter-over-quarter from $6.2 million in Q4 2012.

Novavax (NVAX) Long-Term Investments (2012 - 2013) Analysis & Trends

Novavax's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.1 million for Q1 2013.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $1.1 million in Q1 2013; TTM through Mar 2013 was $1.1 million, a N/A change from a year earlier, with the FY2012 full-year figure at $6.2 million, changed N/A from the prior year.
Long-Term Investments slipped to $1.1 million in Q1 2013 per NVAX's latest filing, from $6.2 million in the prior quarter.
Across five years, Long-Term Investments topped out at $6.2 million in Q4 2012 and bottomed at $1.1 million in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Novavax	788.01 Mn	-2.33 Mn	108.82 Mn	-

Download Data

Date	Value
Mar 31, 2013	1.12 Mn
Dec 31, 2012	6.23 Mn